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Background: Recent reviews suggest that telemedicine solutions for patients with chronic obstructive pulmonary
disease (COPD) may prevent hospital readmissions and emergency room visits and improve health-related quality
of life. However, the studies are few and only involve COPD patients who are in a stable phase or in-patients who
are ready for discharge. COPD patients hospitalized with an acute exacerbation may also benefit from telemedicine
solutions. The overall aim is to investigate a telemedicine-based treatment solution for patients with acute
exacerbation of COPD at home as compared to conventional hospital treatment measured according to first
treatment failure, which is defined as readmission due to COPD within 30 days after discharge.
Methods: COPD patients with acute exacerbation who fulfilled the eligibility criteria and were from two university
hospitals in Denmark were randomized (1:1) by computer-generated tables that allocated treatments in blocks of
four to receive either standard treatment at the hospital or the same standard treatment at home using
telemedicine technology (that is, a video conference system with a touch screen and webcam and monitoring
equipment (spirometer, thermometer, and pulse oximeter)). Patients treated in the telemedicine group were backed
up by an organizational setting securing 24/7/365 online access to the hospital, as well as access to oxygen,
nebulizer therapy, oral medical therapy and surveillance of vital parameters from home monitoring devices. Patients
in both groups were discharged when clinically stable and when fulfilling five pre-specified discharge criteria.
Follow-up was performed at 1, 3 and 6 months after discharge.
The primary outcome was treatment failure defined as readmission due to exacerbation in COPD within 30 days.
Secondary outcomes were death from any cause, prescription of additional antibiotics or steroids, need of
intubation or non-invasive ventilation, emergency room visits, visits to the general practitioner, lung function, bed
days, health-related quality of life, healthcare costs and user satisfaction.
Results: Enrollment of patients started in June 2010 and ended in December 2011. Follow-up ended in May 2012.
Results were analyzed in 2013.
Conclusions: The results may have implications on future hospital treatment modalities for patients with severe
exacerbations in COPD where telemedicine may be used as an alternative to conventional admission.
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According to WHO (World Health Organization), chronic
obstructive lung disease (COPD) will become the third
leading cause of death worldwide in 2030 [1]. More than
430,000 people in Denmark are affected by COPD [2] -
one of the highest prevalence’s in the world - and every
year 23,000 hospital admissions are due to COPD [3].
Concomitantly with an aging population [4] the frequency
of chronic disease is increasing and causing increases in
healthcare costs which in turn has stimulated research
and innovation in technology solutions [5].
Several initiatives supported by technology, among
these telemedicine for patients with chronic disease, are
tested to explore whether alternatives are, when used
correctly, feasible and safe for the patient and cost-
effective compared to conventional care [6].
Clinical evidence is a precondition for implementing
telemedicine solutions into the clinical practice [7].
Rationale
Recent reviews [7-10] with focus on telemedicine for
COPD patients revealed very few randomized clinical tri-
als (RCT’s), and the trials included in the reviews were
small and multimodal with telemedicine as only part of
the intervention, making it difficult to determine the effect
of telemedicine alone. Furthermore the trials comprised
data on newly discharged or stable COPD patients only.
The reviewers concluded that some telemedicine solu-
tions for COPD patients may significantly reduce the
number of hospital readmissions and emergency room
visits [8,9] and may also have a positive effect on health-
related quality of life [9]. A recent study examining the ef-
fect of telehealth on use of secondary care and mortality
has found telehealth to be associated with lower emer-
gency admission rates [6]. The study involved 3,230 pa-
tients with diabetes, chronic obstructive pulmonary
disease, or heart failure who were recruited from practices
in the UK. Evidence is, however, still poor and it is sug-
gested that future trials involving telemedicine for COPD
need to have improved designs and more rigorous atten-
tion to intervention specification and overall aim, to out-
come definition, measurement and health-economic
analyses [7]. It is also mentioned that there is no evidence
that these interventions are embedded in routine clinical
care [7]. In this article we describe the methods of The Vir-
tual Hospital Trial (VHT) where we have endeavored to
overcome aforementioned significant caveats in regard to
design, intervention specification, outcome definitions et-
cetera, and, in addition, we describe how the intervention
was embedded in the routine clinical care at the hospital.
Purpose
The overall aim of this study was to investigate a
telemedicine-based treatment solution for patients withacute exacerbation of COPD at home compared to con-
ventional hospital treatment as measured by first treat-
ment failure, which is defined as readmission due to
COPD within 30 days after discharge. Use of additional
medicine and healthcare services due to COPD, mortal-
ity rate, physiological parameters, and health-related
quality of life, healthcare costs, adverse events and user
satisfaction are also evaluated.
Methods
Design
This was a consecutive, randomized, open, parallel group,
multicentre trial design. The study was planned as a PhD
study with a duration of 3 years, starting with 18 months
of enrollment (June 2010 to December 2011). All en-
rolled patients were followed for 6 months at follow-up
visits 1, 3 and 6 months after discharge. Follow-up fin-
ished in May 2012.
Study settings
Patients were recruited consecutively from the emer-
gency departments at two University Hospitals in the
area of Copenhagen, Denmark.
Patients
Eligibility criteria
The eligibility criteria are listed in Table 1. Patients who
met the inclusion criteria and none of the exclusion cri-
teria were consecutively enrolled in the trial. Staging of
COPD was done according to the GOLD criteria, which
is a global initiative and strategy for the diagnosis, man-
agement and prevention of COPD [11]. The severity
grade was based on historical clinical data obtained
through the patient records. Although the severity grade
of COPD cannot be determined during an exacerbation,
measurements were made prior to randomization to ob-
tain baseline values and to confirm that the patients had
a decreased, obstructive lung function in addition to a
known diagnosis of COPD.
Randomization
Consenting patients, who fulfilled the inclusion criteria
and none of the exclusion criteria, were consecutively
randomized. An external center-used computer gener-
ated tables to allocate treatments in fixed blocks of four
and patients were randomized 1:1 to either intervention
or control group. Each hospital was provided with se-
quentially numbered, sealed and opaque envelopes from
the external center in batches of ten envelopes so that
the allocation sequence was concealed from the investi-
gators assessing and enrolling participants. The sealed
envelope was not opened by the patient until after the
patient had signed a written consent form. The alloca-
tion concealment mechanism was monitored closely by
Table 1 Eligibility criteria
Inclusion criteria Exclusion criteria
• COPD GOLD stage III-IV (that is, FEV1/FVC <0.70 and FEV1 <50% of predicted value). • Need of NIV or manual ventilation at time of randomization
• Acute exacerbation of COPD (for example, Anthonisen et al. definition [12]). • Severely overweightb
• >45 years • Serious comorbidity:
• pH >7.35 • Unstable heart diseasec
• Compliance (see, hear, the ability to understand and carry out self-monitoring tasks). • Poorly regulated diabetesd
• Expected hospitalization > 2 daysa • Malignancy
• Other diseases/conditions that make participation impossible
(dementia, delirium etcetera).
• Temperature >38°C or need for IV antibiotics
• Noncompliance (nursing home resident, tourist etcetera).
• Participation in another trial
ajudged by the attending doctor after initial acute management.
bseverely overweight, causing immobility or Pickwick Syndrome.
cangina pectoris, changes in the electrocardiogram that needed immediate treatment during admission.
dneed for additional insulin during admission.
COPD chronic obstructive pulmonary disease, GOLD the global initiative for chronic obstructive lung disease, FEV1 forced expiratory volume in 1 second, FVC forced vital
capacity, NIV non-invasive ventilation, IV, intravenous.
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resealed and to ensure patients were entered correctly
in the study no matter what allocation the envelope
revealed.
Blinding
Whereas patients and health personnel were not blinded
after randomization, outcome assessors and data analysts
will be blinded to the allocation, however for some of
the secondary outcomes it is difficult for researchers to
remain blind as the patients knew which group they
were in.
Outcomes
Primary outcome
The primary outcome was treatment failure defined as:
Readmission due to an exacerbation in the chronic ob-
structive lung disease within 30 days.
Only readmissions occurring after being discharged
from the telemonitoring group or the usual care group
was designated a readmission. Patients in both groups
were discharged when fulfilling five pre-specified dis-
charge criteria and all telemonitoring equipment was
removed from the patient’s home the same day of
discharge.
Secondary outcomes
The secondary outcomes were; 1) Prescription of add-
itional antibiotics or steroids due to further exacer-
bation, 2) need of non-invasive ventilation (NIV) or
mechanical ventilation, 3) death from any cause,
4) emergency room visits, 5) visits to the general practi-
tioner, 6) lung function (FEV1, FVC, FEV1% predicted),
7) bed days, 8) health-related quality of life, 9) healthcarecosts, 10) applicability, 11) user satisfaction, or 123) ad-
verse events.
Trial organization
One of the study doctors or a specially trained study
nurse screened the electronic patient boards every
morning in the emergency departments at each hospital
for eligible patients. If any possible candidates had been
admitted within the previous 24 hours the patients were
informed in spoken and in written form about the study
and were allowed one hour to decide whether they
wanted to participate or not. Prior to randomization pa-
tients were treated according to the hospital’s protocol
for exacerbations in COPD, which included a scoring al-
gorithm to decide whether a patient was candidate to
treatment with NIV or could continue care at the ward.
The scoring system used measurements of blood gasses,
oxygen saturation, the respiratory frequency and the
level of consciousness to stratify the patients. In the
acute phase (0 to 2 hours) all patients followed a
predetermined regime monitoring arterial blood gasses,
giving nebulized bronchodilator agents, oxygen therapy,
corticosteroids and antibiotics in fixed doses by the at-
tending doctor. After the acute phase it was determined
through the scoring algorithm whether the patient
needed intensive care (NIV/manual ventilation), contin-
ued care at a hospital ward, or could be discharged from
the hospital. The patients who needed continued care at
the ward were thereafter asked to participate in the trial.
Interventions
Experimental group
All patients in the experimental group were trained for
one hour in a secure environment at the hospital in
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technology. A room close to the acute emergency ward
was set up to resemble the patient home with the in-
stalled technology. They received instructions and train-
ing from the health personnel in use of seven items,
following a checklist to ensure they were able to use
and handle the telemedicine technology (TT) equipment
before departure (see list of items´section). The equip-
ment consisted of a videoconference system with a web-
cam and a touch screen, which allowed the patient
direct access to the hospital staff 24 hours a day. Fur-
thermore they were supplied with a pulse oximeter, a
spirometer, a thermometer, a nebulizer for aerosolized
beta2 agonist inhalation, an oxygen compressor and a
medicine box containing antibiotics (oral), prednisone
(oral), sedative (oral) and beta2 agonists (inhalation)
There was a USB connection from each monitoring de-
vice connecting them to the personal computer (PC)
touch screen and data was transmitted via wireless
broadband technology (Figure 1). All patients received
all the equipment, even patients with reasonable oxygen
saturations had to know how to operate the oxygen
compressor in case they would need oxygen later on.
Most patients were familiar with the spirometer, pulse
oximeter, the oxygen supply and medicine from earl-
ier visits to the hospital and from ambulatory visits
so the most unfamiliar thing for the patients to use
was the touch screen. However, since it only had one
possible option (a ‘call hospital’ button on the touchFigure 1 Photo of the telemedicine technology (TT) equipment
used in the Virtual Hospital Trial (VHT). The photo illustrates the
TT equipment used in the patients’ homes and consisted of the
following items shown in the photo from left to right: The medicine
box containing antibiotics, inhalation medicine, corticosteroids and
sedatives; the electronic nebulizer used for inhalation medicine; the
touch screen with a built-in webcam; the oxygen compressor on
the far right standing on the floor;. the spirometer, pulse oximeter,
and thermometer in front of the touch screen were used to send
physiological measurements every day to the hospital. Also, the
patient phone, which is carried by the nurse working in the acute
emergency ward, is in front of the touch screen.screen) 1 hour of training was judged sufficient before
departure.
List of items Checklist and training program for the TT
group
1. Patient can use the “call hospital” button on the
finger touch screen
2. Patient can perform an oxygen saturation and pulse
measurement on the finger tip
3. Patient can perform a lung function measurement
4. Patient can use the oxygen supply
5. Patient can use the nebulizer and corresponding
medicine
6. Patient can perform an “acute” call to the hospital
7. Know when to dial the Danish emergency number 112
Patients in the telemedicine technology group (TT
group) were transported to their own home within a
maximum of 3 to 4 hours after randomization. Upon ar-
rival at home, all patients were asked to redo the seven-
item checklist to ensure that the patients still were able
to perform the necessary procedures of self-management
using the home-monitoring devices, the medication and
the technology. The patients were accompanied home
by a nurse or a doctor together with a technician who
installed the technology and the equipment, a procedure
that normally would last half an hour. All patients kept
the equipment until considered ready for discharge, and
the equipment was physically removed immediately
thereafter.
Scheduled contacts with the hospital staff were agreed
upon before leaving so that the patient was prepared for
daily ward rounds using the video screen at appointed
hours. Additional ward rounds and checkups were only
planned if judged necessary by the attending doctor. Un-
scheduled and acute contacts could always be effectu-
ated by the patient pressing the ‘call hospital’ button on
the touch screen, a close resemblance to the hospital
bed where the patient has a red string to pull when in
need of assistance from a nurse. When a patient acti-
vated the ‘call hospital’ button a phone carried by the
nurse on call would immediately ring, and the nurse
could then choose to either talk directly to the patient
on the phone or to use a video conference system to
contact the patient visually.
If the patient experienced technical problems with the
equipment the patient was instructed to call a direct
phone number instead or to dial the Danish emergency
number 112.
Control group
The medical treatment in both groups followed a strict
standardized treatment program for COPD patients
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treatment´s section).
List of standard treatment Standard medical treatment
regime given in the two groups
 Corticosteroids (oral) Prednisolone 37.5 mg × 1 for
10 days
 Antibiotics (oral) amoxicillin and clavulan acid
500 mg × 3 for 7 days
 Beta-2 agonists and anticholinergics (inhalation)
fenoterol and ipratropium bromide via nebulizer in
specific intervals
 Oxygen therapy (nasal) when needed
 Sedative (oral) levomepromazine 5 mg × 1 only if
needed
The patients allocated to the control group were in-
formed that they would be hospitalized as usual, receiv-
ing the conventional standard hospital treatment for an
exacerbation.
Discharge criteria
Prior to the trial 20 Danish lung specialists were asked
to write down criteria for discharging a patient with an
exacerbation of COPD, and the five most popular cri-
teria were then used in this trial as discharge criteria.
The discharge criteria are not applied systematically in
usual care in Danish hospitals, and some of the criteria
may have delayed discharges that might otherwise have
happened outside the trial situation.
Patients in both groups were considered ready for dis-
charge by the attending doctor if they fulfilled the fol-
lowing five criteria: 1) slept >4 hours without awakening
from respiratory symptoms, 2) FEV1 not decreasing,
3) clinically stable, 4) condition improved during admis-
sion, and 5) oxygen saturation >90 without oxygen or with
the regular oxygen supply if they were long-term oxygen
users.
Implementation and organization of telemedicine
technology at the acute emergency ward
For the first 9 months of inclusion it was the trial physi-
cians and nurses from the telemedicine research unit at
Frederiksberg Hospital who took care of the telemedical
patients and operated the 24/7 ‘call center’. The research
staff either stayed at the hospital during nights or
contacted the patients from their own homes using a PC
with the TT solution embedded. Later on, twenty experi-
enced nurses working at the acute emergency depart-
ment at Frederiksberg University Hospital were trained
4 hours each in operating the TT solution to take over
the calls during evenings and nights. During the daytime
the research unit remained on call. Nursing staff fromthe emergency department were instructed to treat the
telemedical patients exactly the same way as they would
treat them if they had been present at the hospital ex-
cept from the physical contact, which of course was not
possible.
Patients admitted to their own home were represented
with a special color on the electronic patient boards in
the acute emergency ward indicating they were not
physically present in the acute emergency wards but that
they were still admitted or ‘outmitted’, which became an
everyday expression for a patient treated at home. At the
organizational level, the bed in which the patient should
have been placed in was kept empty to reflect a decrease
in workload at the emergency ward having patients
‘outmitted.’ This was very meaningful in that the emer-
gency staff did not feel as if further workload was being
introduced as a result of new treatment modalities.
Sample size
The trial was originally planned to be conducted as a
trial of non-inferiority, which determined the method for
calculating sample size based on a prior study where the
estimated readmission rate was set to be 23.1% [13,14].
The sample size calculation assuming non-inferiority
with a predefined margin of 20% or less, with 5% alpha-
error and 80% power, showed that a patient number of
70 in each group was needed. The inclusion number was
therefore originally set to be 175 patients with an
expected drop out of 20%. However, the required sample
size was not attainable in the planned study duration
and inclusion was stopped as planned after 18 months.
This meant that the study would not reach sufficient
power, but reporting of the sample size determination
will still be done according to the consort statement rec-
ommendation [15].
Collection of data
All patient data were collected in a case record form
(CRF) at baseline, during the intervention, at discharge
and again at follow-ups 1, 3 and 6 months after
discharge.
Data concerning physiological parameters (pulse,
temperature, oxygen saturation, FEV1, and FVC) were
collected by a project nurse or project physician or by
the ordinary staff at the two hospitals during the ward
rounds.
Data concerning readmissions, emergency room visits,
rehabilitation, ambulatory visits, deaths, additional pre-
scriptions of prednisone or antibiotics during hospitaliza-
tion, and length of hospital stays were obtained by
searching the hospital databases, The Danish National Pa-
tient Registry, and the Danish Civil Registration System,
and also by asking the patients at the three follow-up
visits. The only data that were solely self-reported from
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were the health-related quality of life questionnaires and if
there had been any visits to the general practitioner due to
COPD. The validated health-related quality of life ques-
tionnaires used were: the Saint George Respiratory Ques-
tionnaire, (SGRQ), the Clinical COPD questionnaire
(CCQ), and the EQ-5D questionnaire, a standardized in-
strument developed by the Euroqol group.
Also, a user satisfaction questionnaire was handed out
to patients in the TT group at discharge and to the
nurses who engaged with the ‘outmitted’ patients using
the telemedical equipment at the hospital.
The patient user satisfaction questionnaire consisted
of 29 questions. Of these, 24 questions were presented
in a 5-point Likert-scale (1 strongly disagree through 5
strongly agree) and 5 close-ended questions (yes/no).
The questionnaire covers the patient experience in dif-
ferent settings such as the daily ward round, acute calls,
the equipment use, and the patient’s general experience
of the at home admission with telemedicine technology.
The cognitive status of each patient was evaluated in a
substudy using a neuropsychological test battery, includ-
ing verbal learning, memory capacity and attention and
was also evaluated by a self-reported questionnaire: the
Subjective Cognitive Functioning (SCF). In the substudy,
the patient’s functional status was evaluated by the In-
strumental Activity of daily living (IADL)questionnaire.
Another substudy evaluated the patients’ self-efficacy.
Self-efficacy was measured using ‘The COPD self-efficacy
scale’, which has been validated in a Danish version [16].
Statistics
All analyses will be done using SAS software version 9.3
http://support.sas.com/software/93. Time to readmission
after discharge due to an exacerbation will be assessed
using a stratified Cox regression to relax the assump-
tions of proportional hazards. Differences in readmission
rate over time will be assessed using multilevel mixed-
effects linear regression analysis with unstructured vari-
ance matrix where the baseline values of the outcomes
are used as covariates. P values below 0.05 will be con-
sidered significant for the primary outcome, and P
values below 0.01 will be considered significant for sec-
ondary outcomes. Skewed variables will be power
transformed if possible; otherwise, the variables will be
transformed into dichotomous responses. Missing values
will be replaced using multiple imputations [17]. Survival
times will be plotted in a Kaplan-Meier survival curve.
Differences between the two groups in prescription of
additional antibiotics or steroids due to further exacer-
bation, need of non-invasive ventilation or mechanical
ventilation, emergency room visits, visits to the general
practitioner, lung function, bed days, and adverse events
will be analyzed with an unpaired Student t-test if dataare normally distributed or Mann-Whitney test if not.
All categorical data will be analyzed with Chi-square
test or Fishers exact test as appropriate. For the health-
related quality of life scores, differences from baseline,
both within and between study groups, and 95% confi-
dence intervals will be calculated. All analyses will be
done on the principle of intention to treat.
Adverse events
All adverse events and adverse device events that oc-
curred during the 30-day study observation period will
be reported in the final paper. An adverse event is de-
fined as any unwanted event happening to the patient
during the clinical trial while using the medical equip-
ment or after using the equipment regardless of whether
there is a connection between the use of the equipment
and the unwanted event or not. A serious adverse event
was defined as an event that leads to death, to life
threatening damage or disease, to permanent damage to
the body, to permanent disability, or to surgical or med-
ical treatment to avoid these serious events. Also events
leading to hospital admission or prolongation of the hos-
pital stay were considered serious events. The formal
stopping rule was that the study would be stopped after
18 months of inclusion or before if any serious situations
occurred that might put a patient’s welfare at risk. This
study is a clinical trial concerning telemedical equipment
and all adverse events that may or may not be related to
the use of the telemedical equipment will be reported in
the CRF and in the final report.
Ethical considerations
The study was approved by the Danish Regional Com-
mittee on Scientific Ethics (protocol number H-2-2010-
021) and the Danish Data Protection Agency (journal
number 2010-41-4684). The trial is registered on
clinicaltrials.gov (NCT01155856) and was conducted in
accordance with the principles of GCP and The Helsinki
Declaration. All participants signed written informed
consent forms before randomization. By signing the con-
sent form the patient accepted that technicians from the
IT company, Viewcare, would install the telemedical
equipment in their home and would remove it again at
discharge. Patients also accepted having the equipment
turned on at all times so that it was always possible to
make contact. Patients in the control group were asked
to fill out questionnaires and had three follow-up visits,
but otherwise had no inconveniences in connection to
their participation in the trial.
Results
From June 2010 to December 2011, 57 patients were
randomized. Average monthly recruitment for the trial
was 3,2 patients. Follow-up visits ended in May 2012.
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In Denmark, 28.5% COPD patients were readmitted
within 1 month after discharge [18]. The study design
for the VHT was directed at selecting the population of
COPD patients who are most frequently hospitalized
and would potentially benefit from the TT solution in
terms of reduced risk of readmissions, emergency room
visits, increased health-related quality of life etcetera The
design and methods of the VHT differs from previous
trials investigating telemedicine solutions for COPD pa-
tients. First, only COPD patients with an acute need of
hospital treatment were included. Secondly, the patients
received comparable medical treatment and attention in
both groups with the only difference being the location
of the patient, which made it a true ‘telemedical’ inter-
vention with no physical contact with the health
personnel. Thirdly, pre-specified discharge criteria were
necessary to make the discharges in both groups as un-
biased and objective as possible. Fourthly, this trial was
based on a telemedical intervention that was actually
embedded in the routine clinical care by staff nurses not
otherwise involved in the study at the hospital, and the
results may have implications on future use and imple-
mentation of telemedicine in the hospital sector. Twenty
acute emergency ward nurses were trained to deal with
telemedical patients from two hospitals, and these patients
became part of their daily routine. Their experiences with
the TT solution may be valuable for other researchers in
the field of organizational research since there is lack of
reporting in the literature for implementation of telemedi-
cine interventions in the daily routine care [7].
When it comes to the internal validity of the study, we
believe we have taken several initiatives to minimize bias
by using consecutive enrollment and central randomiza-
tion. Due to the nature of the trial it has not been pos-
sible to blind patients and healthcare personnel, which
introduces the risk of performance, attrition and assess-
ment bias. However, risk of bias may be high for some
outcomes and low for others. For example, knowledge of
the assigned intervention may affect behavioral out-
comes (such as number of hospital visits), while not af-
fecting physiological outcomes or mortality. Thus,
assessments of risk of bias resulting from lack of
blinding may need to be made separately for different
outcomes. However, unblinded studies can take other
measures to reduce the risk of bias, such as treating pa-
tients according to a strict protocol to reduce the risk of
differential behaviors by patients and healthcare pro-
viders. We believe we have tried to reduce the risk by
treating the patients according to a very strict medical
protocol and by discharging them according to the same
discharge criteria.
The validity of administrative data such as number of
admissions, emergency visits, discharge, etcetera is veryhigh in Denmark, due to The Danish National Patient
Registry, which has collected nationwide data on all
somatic hospital admissions since 1977 and on all outpa-
tients and emergency patients since 1995.
Conclusions
The VHT is to our knowledge the first trial to investi-
gate an at-home admission supported by TT compared
with a conventional admission due to an exacerbation of
COPD. We believe it is the first randomized trial to de-
scribe a method where the telemedicine solution was ac-
tually implemented in the daily routine clinical care at
an acute emergency hospital ward during evening and
nights.
The method developed in this study allowed for one
hospital to take over the care of COPD patients from an-
other hospital and potentially for even more hospitals.
This is the first step of a potential re-organization of
hospital healthcare services using telemedicine to con-
nect to other hospitals creating new collaborations and
new offers for the patients.
The results of the trial may have implications for fu-
ture hospital treatment options, as patients can be
equipped with telemedicine solutions to avoid expensive
hospital admittances when their disease deteriorates.
Further, this study is an example of a health service
transformation mediated by welfare technology.
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